In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results The Obesity Wars of 2026 continue: Novo's Miss, Lilly's Supremacy, and the Quality of Weight Loss Pivot Retatrutide vs. Tirzepatide: The Next Gen GLP 1 Showdown Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased Semaglutide, Tirzepatide, Retatrutide and Cagrilintide are often lumped together, but they are not doing the same thing. : r Wegovy